Toxicology testing in pain care should improve safety, not punish or stigmatize patients. It can provide information about prescribed medication, unreported substances, and combinations that increase overdose risk, but it cannot replace a clinical conversation.
When testing may be considered
The CDC recommends considering benefits and risks before starting opioids and periodically during therapy. Frequency should reflect the patient’s circumstances and a standardized clinical policy—not stereotypes or assumptions about identity.
Explain the plan first
Clinicians should tell patients what is being tested, expected results, costs, and how unexpected findings will be handled. There should be a plan before ordering the test. Testing should not be described as a trap or as proving whether someone is “good” or “bad.”
Panel limitations
A generic opiate immunoassay may detect morphine-related compounds yet miss fentanyl, methadone, buprenorphine, or oxycodone unless specifically included. Some benzodiazepines are poorly detected by common screens. Clinicians must know the local assay.
Unexpected absence of a prescribed drug
Possible explanations include timing, as-needed use, assay limitations, low concentration, laboratory or collection error, stopping because of side effects, or diversion. Discuss the result and use definitive testing when it will change a major decision.
Unexpected presence of another substance
Consider a prescription, metabolite, cross-reaction, nonprescribed use, or specimen error. Confirmation and consultation with the laboratory can clarify. The result should be used to reduce risk—for example by revisiting the treatment plan, offering naloxone, or assessing for a substance-use disorder.
Avoid harmful responses
CDC advises clinicians not to dismiss patients solely because of a toxicology result. Abrupt termination can increase withdrawal, overdose, and loss of care. If therapy changes, use an individualized plan and offer evidence-based treatment when opioid use disorder is identified.
What a urine result cannot show
Urine does not reliably reveal dose, exact timing, or impairment. Quantitative concentration is affected by hydration and metabolism and should not be used as a simple measure of how much medication a patient took.
For the technical process, see Laboratory Confirmation Testing.
Sources
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain
- SAMHSA: Clinical Drug Testing in Primary Care
Medical review: October 29, 2026.